Peter Lynch fit · Growth at a reasonable price (GARP)
Is Neurocrine Biosciences, Inc. (NBIX) a Peter Lynch Stock?
Some GARP characteristics, but growth or valuation is stretched.
65/100
BMixed signals
6/6 criteria passed
+10 sector-quality lift. Top-quintile within its sector on 5 of 5 quality metrics. Raw pillar score 55 → lifted to 65 before grade derivation.
Peter Lynch's Criteria, Applied to NBIX
PEG ≤ 1.0
key0.45
EPS CAGR ≥ 15%
key50.0%
Revenue CAGR ≥ 10%
26.0%
Net margin > 0
21.6%
How NBIX Scores on Other Strategies
Live Financial Snapshot
Market cap
$15.88B
P/E (TTM)
22.6x
ROIC (TTM)
13.68%
Gross margin
98.17%
Other Peter Lynch fit reports
Frequently Asked Questions
What is NBIX's Peter Lynch fit score?
NBIX scores 65/100 on our Peter Lynch fit engine - grade B. Some GARP characteristics, but growth or valuation is stretched.
Does Peter Lynch actually own NBIX?
Our score is computed from financial fundamentals against Peter Lynch's published criteria. We don't claim that Peter Lynch personally owns or recommends NBIX.
How often is this score updated?
NBIX's Peter Lynch fit score is recomputed daily from the latest TTM financials. The page below shows when it was last refreshed.
Educational tool, not investment advice. Scores are computed from publicly-available financial data against published investing-strategy criteria. We do not claim that Peter Lynch personally owns or recommends NBIX.